CYR61 suppresses growth of human malignant melanoma.
Cysteine-rich protein 61 (CCN1/CYR61) is an important marker of proliferation and metastasis in malignant melanoma, making it a potential target for melanoma treatment. In this study, we compared the expression of CRY61 in Chinese patients with malignant melanoma with its expression in patients with other skin tumors or with no skin pathological conditions. We examined the effects of anti-human CYR61 monoclonal antibody on proliferation and evaluated the changes in CYR61 expression and cell proliferation in response to treatment with either epirubicin or interferon (IFN)-α. CYR61 was expressed at lower levels in patients with malignant melanoma than in patients with other skin tumors or with no pathology. Following the treatment of B16 cells with epirubicin and IFN-α, CYR61 levels increased, cell growth was inhibited, and proliferating cell nuclear antigen expression decreased. Thus, CYR61 could become a therapeutic target for malignant melanoma patients with high CYR61 expression.
Department of Dermatology and Dermatologic Surgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China.
Jun
J
Chen
Department of Dermatology and Dermatologic Surgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China.
Yang
Y
Liu
Department of Dermatology and Dermatologic Surgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China.
Qilin
Q
Sun
Department of Dermatology and Dermatologic Surgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China.
Beiqing
B
Wang
Department of Immunology, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China.
Ningli
N
Li
Department of Dermatology and Dermatologic Surgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China.
Xiangdong
X
Chen
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D055515:Cysteine-Rich Protein 61 / Q000235:genetics*; D015251:Epirubicin / Q000008:administration & dosage; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D051379:Mice; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
D000911:Antibodies, Monoclonal; C501848:CCN1 protein, human; D055515:Cysteine-Rich Protein 61; D016898:Interferon-alpha; D015251:Epirubicin